At third visit, which was 180 days after entering the study, the levels of prolactin were comparable in all groups (severe COVID-19: 275.74 ± 36.33; mild or moderate COVID-19: 260.85 ± 68.30; control: 275.0 ± 50.29 ng/mL) (Figure 4b). This evidence concerns the gene PRL and COVID-19.